title: [Long-term survival with gemcitabine and docetaxel for renal leiomyosarcoma : a case report].
abstract: A 64-year-old woman who complained of abdominal pain underwent right radical nephrectomy under the clinical diagnosis of renal cell carcinoma in January, 2006. The pathological diagnosis was leiomyosarcoma originating from the kidney. Follow-up computed tomography revealed 2 small nodules in the left lung 15 months after nephrectomy. A lung nodule resected with video-assisted thoracic surgery (VATS) was identified as metastatic leiomyosarcoma. Since the pulmonary metastases progressed after VATS, systemic chemotherapy with gemcitabine and docetaxel (GD therapy) was started. The lung metastases responded well, and a durable partial response was achieved for 29 months. Subsequently, the patient developed new pulmonary metastases and pancreatic metastasis. Despite this disease progression, we elected to continue GD therapy, since the patient's performance status and quality of life were favorable during the treatment. So far, the GD therapy has been continued for another 23 months, for a total of 41 treatment cycles, with few adverse events. Although multiple metastases have slowly progressed, the patient has maintained good performance status in the outpatient clinic. In the present case, GD therapy seems to have been beneficial for survival, as metastatic renal leiomyosarcoma is considered to have an extremely poor prognosis.
authors.affiliation: The Department of Urology, University of Tsukuba, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Nagumo
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Kimura
authors.forename: Daishi
authors.initials: D
authors.lastname: Ichioka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Uchida
authors.forename: Takehiro
authors.initials: T
authors.lastname: Oikawa
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suetomi
authors.forename: Jun
authors.initials: J
authors.lastname: Miyazaki
authors.forename: Koji
authors.initials: K
authors.lastname: Kawai
authors.forename: Chigusa
authors.initials: C
authors.lastname: Nagata
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nishiyama
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000556:secondary; D043823:Taxoids / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine